From Nasdaq: 2025-06-17 18:15:00

Medpace (MEDP) closed at $297.92, down -1.02% from the previous session, trailing S&P 500, Dow, and Nasdaq. Over the past month, Medpace lost 1.53%, outperforming the Medical sector but lagging behind the S&P 500. Analysts project an EPS of $2.99 and revenue of $539.75 million for Medpace’s upcoming earnings disclosure.

Investors should keep an eye on Medpace’s valuation metrics, with a Forward P/E ratio of 23.68 and a PEG ratio of 5.43. The Medical Services industry’s average PEG ratio is 1.54, indicating Medpace may be trading at a premium. The industry ranks in the top 23% of all industries, showing strong performance potential.

Experts recommend 7 elite stocks, including Medpace, as the “Most Likely for Early Price Pops.” These top-rated stocks have historically outperformed the market with an average gain of +23.5% per year since 1988. Investors can access the full list of recommended stocks for the next 30 days to capitalize on potential price increases.



Read more at Nasdaq: Medpace (MEDP) Dips More Than Broader Market: What You Should Know